PMID: 42260119
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Ludwig Mette Q, Coester Bernd, Gordian Desiree et al.
Nature metabolism · 2026
Research Library
Cagrilintide
38 papers indexed
PMID: 42452898
Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi Abdulhameed, le Roux Carel W
Diabetes, obesity & metabolism · 2026
PMID: 41549439
Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
Chung Chae Won, Kim Jaetaek
Journal of obesity & metabolic syndrome · 2026
PMID: 41344603
Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Rejili Mokhtar, Hussain Md Sadique, Khan Yumna et al.
Vascular pharmacology · 2026
PMID: 41627368
Bariatric Surgery in the Era of GLP1RA: A Narrative Review.
Muhundan Mathula, Dash Satya
Advances in therapy · 2026
PMID: 42296503
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Damen Johanna A A, Idema Demy L, Vernooij Robin W M et al.
Annals of internal medicine · 2026
PMID: 42208956
Beyond weight loss: multisystem benefits of obesity medications.
Savas Mesut, Kuckuck Susanne, Boon Mariëtte R et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 41328546
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Verma Subodh, Böttcher Morten, Brown Paul et al.
Hypertension (Dallas, Tex. : 1979) · 2026
PMID: 41759565
CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
Gadelmawla Ahmed Farid, Hammad Noha, Atta Karim et al.
The American journal of cardiology · 2026
PMID: 42180166
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
Rao Hammad, Kumar Sumet, Ali Sheikh Muhammad Ebtehaj et al.
Journal of diabetes and metabolic disorders · 2026
PMID: 41259765
Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
Krakauer Jesse C, Krakauer Nir Y
The New England journal of medicine · 2026
PMID: 41259766
Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
Lnu Vivek, Noor Fatima
The New England journal of medicine · 2026
PMID: 41259767
Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
Chi Hao, Yang Hua, Deng Youping
The New England journal of medicine · 2026
PMID: 41259768
Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
Garvey W Timothy, Osorto Contreras Cynthia Karenina, Davies Melanie J
The New England journal of medicine · 2026
PMID: 41259769
Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
Davies Melanie J, Broholm Christa, Garvey W Timothy
The New England journal of medicine · 2026
PMID: 42251856
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Rosenstock Julio, Billings Liana K, Gajria Reena et al.
Lancet (London, England) · 2026
PMID: 42251859
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
Buse John B, Bajaj Harpreet S, Dalskov Stine-Mathilde et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42251858
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
Scheen André J
The lancet. Diabetes & endocrinology · 2026
PMID: 42260118
Cellular loci for cagrilintide action identified.
Hevesi Zsofia, Harkany Tibor
Nature metabolism · 2026
PMID: 41933725
Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
Mishra Nikunja Kishor
Clinical nutrition ESPEN · 2026
PMID: 42207966
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
Hamarsheh Sultan, Jaber Abdel Rahman, Abu-Khazneh Omar et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 42419792
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Nong Kailei, Shi Qingyang, Xie Xinran et al.
BMJ (Clinical research ed.) · 2026
PMID: 42498824
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
Lewis Jo Edward, Montaner Mireia, Nuzzaci Danae et al.
Nature metabolism · 2026
PMID: 42366647
Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.
Gulisano Walter, Ter-Borch Gitte, Brown Paul et al.
Journal of diabetes science and technology · 2026
PMID: 41834765
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
Ahmed Muhammad, Hassan Muhammad, Tahir Muhammad et al.
Diabetes, obesity & metabolism · 2026
PMID: 42009015
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Yamauchi Toshimasa, Becker Niels-Peter, Hagemann Christoffer Andersen et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42251860
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Aroda Vanita R, Buzzetti Raffaella, Dalskov Stine-Mathilde et al.
The lancet. Diabetes & endocrinology · 2026
PMID: 42456707
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
Loomba Rohit, George Jacob, Castera Laurent et al.
The lancet. Gastroenterology & hepatology · 2026
PMID: 42503495
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Busetto Luca, Contreras Cynthia Osorto, Christensen Mikkel Hovden et al.
Diabetes, obesity & metabolism · 2026
PMID: 41702251
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
Alhalabi Hana, Borschel Lisa, Le Foll Christelle et al.
Journal of pharmaceutical and biomedical analysis · 2026
PMID: 41747885
Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Bailey Clifford J, Flatt Peter R, Conlon J Michael
Peptides · 2026
PMID: 41852165
Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
Old Victoria, Davies Melanie, Denniff Matthew et al.
Journal of cachexia, sarcopenia and muscle · 2026
PMID: 41901137
New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
Pardali Eleni C, Gkouskou Kalliopi K, Cholevas Christos et al.
Nutrients · 2026
PMID: 42175595
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Kamrul-Hasan A B M, Khalil Ibrahim, Mahajan Kunal et al.
Endocrinology, diabetes & metabolism · 2026
PMID: 41948476
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Lempesis Ioannis G, Dalamaga Maria
Metabolism open · 2026
PMID: 42228334
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
Nielsen Mette J F, Becker Niels-Peter, Duus Helene H Hansen et al.
Clinical pharmacokinetics · 2026
PMID: 41259764
Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
Fogacci Federica, Cicero Arrigo F G
The New England journal of medicine · 2025
PMID: 41375628
Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.
Martínez-Castelao Alberto, Górriz José Luis, Fernández-Fernández Beatriz et al.
Journal of clinical medicine · 2025
For research use only. This index links to third-party literature. Nothing here constitutes medical advice.